| Filed On | Filing |
|---|---|
| 14 Oct 2026 |
8-K: Other Events
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the “Company”), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey ... |
| 02 Oct 2026 |
Form 4: Pieper Steven, See Remarks
Sold 5,000 shares ($47K) |
| 02 Oct 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 15,000 shares ($141K) |
| 02 Oct 2026 |
Form 4: Hecht Beth, See Remarks
Sold 16,666 shares ($157K) |
| 01 Oct 2026 | 144 |
| 29 Sep 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 25,000 shares ($250K) |
| 28 Sep 2026 | 144 |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Copyright © 2021-2026 Xeris Pharmaceuticals, Inc. All rights reserved. Today’s Agenda 2 1 Welcome & Introductions Allison Wey — SVP, Investor Relations 2 Becoming the Next Great Biopharmaceutical Company John Shannon – Chairman and Chief... |
| 01 Sep 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 15,000 shares ($127K) |
| 01 Sep 2026 |
Form 4: Hecht Beth, See Remarks
Sold 16,666 shares ($141K) |
| 01 Sep 2026 |
Form 4: Pieper Steven, See Remarks
Sold 5,000 shares ($42.5K) |
| 21 Aug 2026 |
Form 4: Shannon John Patrick Jr, Director
Gave up 36,645 shares to cover exercise price or tax ($296K) |
| 21 Aug 2026 |
Form 4: McCulloch Kevin, See Remarks
Gave up 21,918 shares to cover exercise price or tax ($177K) |
| 12 Aug 2026 |
Form 4: Pieper Steven, See Remarks
Sold 5,000 shares ($42.5K) |
| 12 Aug 2026 | 144 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 04 Aug 2026 |
Form 4: McCulloch Kevin, See Remarks
Sold 15,000 shares ($120K) |
| 04 Aug 2026 |
Form 4: Hecht Beth, See Remarks
Sold 16,666 shares ($134K) |
| 31 Jul 2026 | SCHEDULE 13G |
Loading...
